Vancomycin
22
3
3
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
4.5%
1 terminated out of 22 trials
91.7%
+5.2% vs benchmark
41%
9 trials in Phase 3/4
45%
5 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (22)
Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
Precision Dosing of Vancomycin in Critically Ill Children
Antibiotic Dosing in Pediatric Intensive Care
Vancomycin Reduction Practices (VRP) in the NICU
Continuous vs. Intermittent Infusion Vancomycin
Optimal Treatment for Recurrent Clostridium Difficile
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
Clinical Decision Support Tool for Vancomycin Dosing in Children
Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol
The Clinical Validation of a Dried Blood Spot Method for Vancomycin and Creatinine
Model-informed Precision Dosing of Vancomycin in Adults
First Time Right of Vancomycin
Pharmacokinetics of Preoperative Vancomycin
Intracameral Antibiotic Safety Study
Vancomycin Dose Adjustments Comparing Trough Levels to The AUC/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population
Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology
Intrawound Vancomycin Prophylaxis for Neural Stimulator
Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
The Influencing Factors of Vancomycin Trough Level and the Rate Achieving the Target Trough Level